<DOC>
	<DOCNO>NCT00983554</DOCNO>
	<brief_summary>Subjects randomize 4 study group : 1 . Placebo ; 2 . Anastrazole Testosterone ; 3 . Dutasteride Testosterone ; 4 . Testosterone . A 2 step euglycemic clamp , body composition dual X-ray absorptiometry scan , hormone lipid assay perform monitor metabolic effect treatment group . We hypothesize increase testosterone level would increase lean mass , decrease fat mass improve insulin sensitivity . We hypothesize improvement metabolic profile would decrease anastrazole improve dutasteride , give conjunction T administration .</brief_summary>
	<brief_title>Metabolic Effects Steroids Obese Men</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<criteria>free T level lower 25 % normal range BMI ≥30kg/m2 waist circumference ≥100cm pituitary tumor HIV infection Klinefelter 's syndrome Kallman 's syndrome uncontrolled hypertension diabetes congestive heart failure chronic lung disease acute coronary syndrome PSA &gt; 4µg/L aspartate aminotransferase ( AST ) &gt; 3x upper limit normal use medication might affect weight loss , muscle bone metabolism androgen metabolism , action clearance . involvement daily resistance training high endurance exercise alcohol drug dependence obstructive sleep apnea</criteria>
	<gender>Male</gender>
	<minimum_age>24 Years</minimum_age>
	<maximum_age>51 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>testosterone</keyword>
	<keyword>insulin</keyword>
	<keyword>obesity</keyword>
	<keyword>aromatase</keyword>
	<keyword>5 alpha reductase</keyword>
</DOC>